Testing a novel nanofibre scaffold for utility in bone tissue regeneration

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Orthopedic Research

Background:

• Bone regeneration is complex, influenced by wound bed characteristics and individual health.
• Tissue-engineered scaffolds and growth factors like bone morphogenetic protein 2 (BMP2) are used clinically.
• BMP2 has limitations, including inflammation, ectopic bone formation, and graft failure.

Purpose of the Study:

• To compare the efficacy of a nanofiber scaffold (Talymed) versus an absorbable collagen sponge (ACS) in accelerating BMP2-induced bone healing.
• To evaluate bone regeneration quality and quantity using microCT, biomechanical, and histological analyses.

Main Methods:

• 155 adult wild type mice underwent skull defects treated with ACS or Talymed scaffolds.
• Scaffolds were loaded with control, low, medium, or high doses of BMP2.
• Assessments were performed at 4 and 8 weeks post-implantation.

Main Results:

• Talymed scaffolds decreased bone volume, bone formation rate, and alkaline phosphatase activity compared to ACS/BMP2.
• Talymed scaffolds resulted in greater bone hardness at 4 weeks, but this difference diminished by 8 weeks.
• ACS/BMP2 combinations demonstrated superior overall bone formation and remodeling compared to Talymed.

Conclusions:

• The nanofiber scaffold (Talymed) improved bone quality (hardness) at an early time point (4 weeks).
• However, Talymed's inhibition of bone formation and remodeling processes limited its overall efficacy.
• The current clinical standard, ACS/BMP2 therapy, remains more efficacious for BMP2-induced bone healing.